The Moment Of Truth For Three Alzheimer’s Drugs Beckons: What To Expect

Eisai/Biogen And Roche Phase III Readouts Expected Soon

 
• By Andrew McConaghie

After the Aduhelm controversy, Eisai/Biogen, Roche and Lilly are lining up Phase III results for their candidates which, against the odds, they hope could finally represent real progress in Alzheimer’s treatment. Scrip takes a look at the key questions surrounding the field as the drugs await their fate.

Alzheimer's jigsaw
After the Aduhelm controversy, there is hope these drugs could offer a true breakthrough for people with early stage Alzheimer's. • Source: Shutterstock

More from Neurological

More from Therapy Areas